Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:World J Hepatol
Asıl Yazarlar: Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Baishideng Publishing Group Inc 2017
Konular:
Observational Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://ncbi.nlm.nih.gov/pubmed/28469811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i11.551
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller